anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Liver transplantation constitutes the only curative treatment for patients with end-stage liver disease. Advances in the field have led to favourable short- and medium term (1-3 year) post-transplant survival rates, but improvement in long-term survival rates remains disappointing. Due to the immunosuppressive therapy, a sedentary lifestyle and a poor recovery of post-transplant physical fitness, the proportion of liver transplant recipients that develop a new-onset or a deteriorating unfavourable cardiovascular risk profile is alarmingly high, and cardiovascular disease is the leading cause of death in this population. By consequence, in order to improve long-term outcome after liver transplantation, prevention of cardiovascular disease should be prioritized. The investigators are convinced that the challenge of cardiovascular disease and lack of physical fitness in liver transplant recipients should and can be addressed by subjecting these patients to a structured physical rehabilitation program. The aim of this project is implement a structured, individually-tailored, home-based but supervised physical rehabilitation and maintenance program for de novo liver transplantation recipients, and to demonstrate the feasibility and safety of such approach as well as its efficacy to improve physical fitness. The program will consist of a 2-phase intervention of i) home-based exercise training (aerobic exercise training as well as strength, flexibility and stability exercises under in-person and subsequently remote guidance) and ii) an 15-month maintenance phase of physical activity. This program will be studied in an open-label randomized trial where the regimen will be compared with a regimen of standard of posttransplant care. In addition to the interventional arm, two different regimens of exercise training intensity will also be studied.
BACKGROUND: Klebsiella pneumoniae is a common Gram-negative bacterium. Blood infection caused by K. pneumoniae is one of the most common causes of human sepsis, which seriously threatens the life of patients. The immune status of peripheral blood mononuclear cells (PBMCs) based on single-cell RNA sequencing (scRNA-seq) in acute stage and recovery stage of sepsis caused by K. pneumoniae bloodstream infection has not been studied.
METHODS: A total of 13 subjects were included in this study, 3 healthy controls, 7 patients with K. pneumoniae bloodstream infection in the acute stage (4 patients died), and 3 patients in the recovery stage. Peripheral blood of all patients was collected and PBMCs were isolated for scRNA-seq analysis. We studied the changes of PBMCs components, signaling pathways, differential genes, and cytokines in acute and recovery stages.
RESULTS: During K. pneumoniae acute infection we observed a decrease in the proportion of T cells, most probably due to apoptosis and the function of T cell subtypes was disorder. The proportion of monocytes increased in acute stage. Although genes related to their phagocytosis function were upregulated, their antigen presentation capacity-associated genes were downregulated. The expression of IL-1β, IL-18, IFNGR1 and IFNGR2 genes was also increased in monocytes. The proportion of DCs was depleted during the acute stage and did not recover during sepsis recovery. DCs antigen presentation was weakened during the acute stage but recovered fast during the recovery stage. pDCs response to MCP-1 chemokine was weakened, they recovered it quickly during the recovery stage. B cells showed apoptosis both in the acute stage and recovery stage. Their response to complement was weakened, but their antigen presentation function was enhanced. The proportion of NK cells stable during all disease's stages, and the expression of IFN-γ gene was upregulated.
CONCLUSION: The proportion of PBMCs and their immune functions undergo variations throughout the course of the disease, spanning from the acute stage to recovery. These findings provide new insights into the mechanism of PBMCs immune function during K. pneumoniae bloodstream infection sepsis and recovery and sets the basis for further understanding and treatment.
PROBLEM TO BE SOLVED: To obtain a composition for oral cavity excellent in effect of inhibiting adhesion of bacteria in the oral cavity to teeth surface and their proliferation and capable of inhibiting bacterial plaque formation, containing a cationic polymer and a noncationic antibacterial agent as active ingredients. SOLUTION: This composition for oral cavity contains 0.0001-5wt.% of a cationic polymer (e.g. dimethyl diallyl ammonium chloride-contg. polymer) and 0.0001-5wt.% of a noncationic antibacterial agent (e.g. a halogenated disphenyl ether) in such a weight ratio as to be (0.5-99.5) pts.wt./(0.5-99.5) pts.wt., and pref. contains 0.0001-5wt.%, on a fluorine basis, of a fluoride. This composition is effective for preventing oral cavity diseases such as dental caries and periodontosis.
Nonsteroidal anti-inflammatory drugs (NSAIDs) are the most commonly consumed drugs worldwide for the relief of pain and arthritis. However, the use of NSAIDs increases the risk of ulcer bleeding by 4-fold. Current evidence indicates that combination of conventional NSAIDs and a proton pump inhibitor (PPI) reduces the risk of ulcer complications. The alternative strategy is to replace conventional, non-selective NSAIDs with NSAIDs selective for cyclooxygenase-2 (COX-2 inhibitors). Recently, there are concerns about the cardiovascular safety of COX-2 inhibitors and conventional NSAIDs. Because of such concern, patients requiring anti-inflammatory analgesics who have cardiovascular risk factors (e.g. smoking, hypertension, hyperlipidemia, diabetes) should receive prophylactic low-dose aspirin. However, concomitant low-dose aspirin negates the gastric sparing effect of COX-2 inhibitors and augments the gastric toxicity of nonselective NSAIDs. Thus, gastroprotective agents such as PPIs should be co-prescribed to patients with high ulcer risk who are taking aspirin plus a COX-2 inhibitor or a nonselective NSAID.
Fatsing for at least 6 hours pre-operative, No restriction of IV fluids and traditional analgesia including opiates. Post-operative Ambulation-as per patients' own request, Removal of urinary catheter when patient ambulates, patient will keep fasting for 3 days postoperative, oral fluids for 3 days, semi-solid for another 3 days and then can take full diet, removal of nasogastric tube just before starting oral fluids, drain removal just before discharge.
PROBLEM TO BE SOLVED: To conveniently and accurately evaluate improvement effect for slack of skin in vitro by measuring the strength of a specific substance which enhances the gel strength containing in a test sample. SOLUTION: This evaluation is to measure the strength of collagen gel filled up animal cells containing a test sample. As the animal cells, normal skin fibroblast, pulmonary fibroblast, gingival fibroblast, chondromatous cell, liver cell and vascular endothelial cell are illustrated. Among them, skin fibroblast and pulmonary fibroblast are particularly preferable. As the animals providing cells, human, mouse, rat and rabbit are preferable. As these cells, both of primary cultured cells and aged cells of which subculture is repeated in vitro may be used. In addition, either of cells arising from fetus and aged man may be also utilized. As collagens used here, collagens arising from human, mouse, rat, rabbit, guinea pig and cattle are preferable. As methods for measuring the strength of collagen gel, stress relaxation test, cutting test and creep test are illustrated.
Most adverse reactions have been mild. The incidences listed in the following table are derived from 12-week comparative double-blind, parallel design trials in hypertensive patients given pindolol as monotherapy, given various active control drugs as monotherapy, or given placebo. Data for pindolol and the positive controls were pooled from several trials because no striking differences were seen in the individual studies, with one exception. When considering all adverse reactions reported, the frequency of edema was noticeably higher in positive control trials (16% pindolol vs. 9% positive control) than in placebo controlled trials (6% pindolol vs. 3% placebo). The table includes adverse reactions either volunteered or elicited, and at least possibly drug-related, which were reported in greater than 2% of pindolol patients and other selected important reactions.

The following selected (potentially important) adverse reactions were seen in 2% or fewer patients and their relationship to pindolol is uncertain. CENTRAL NERVOUS SYSTEM: anxiety, lethargy; AUTONOMIC NERVOUS SYSTEM: visual disturbances, hyperhidrosis; CARDIOVASCULAR: bradycardia, claudication, cold extremities, heart block, hypotension, syncope, tachycardia, weight gain; GASTROINTESTINAL: diarrhea, vomiting; RESPIRATORY: wheezing; UROGENITAL: impotence, pollakiuria; MISCELLANEOUS: eye discomfort or burning eyes.
Appropriate study power will be achieved with 35 participants in the weight loss group and 35 participants in the weight maintenance control group (see Data Analysis and Statistical Considerations). We will recruit and enroll obese (BMI ≥29 - ≤40) men and women, age 18 to 45, with no previous history of lower extremity injury, no evidence of symptoms OA, no knee misalignment (neutral alignment between 178° and 182°), or other injury that would prevent them from performing the walking task required by this study. All inclusion criteria specific to knee injury, OA, and alignment will be verified by MRI scan. All participants in this study will be informed of the risks involved. Upon expressing interest in study participation, participants will be asked questions to determine whether they are free of lower extremity injury and their height and weight will also be recorded to determine their BMI. Potential participants will be pre-screened by phone using a phone script with a list of questions. Once it is determined they meet all study inclusion criteria, they will be invited to attend a consent meeting.
The invention discloses a method for implementing pain protocols and reducing patient recovery times. The invention has a dynamically updated database of pain protocols that a consultant can use to improve medical facility conditions. The database contains training information, pain protocol techniques, and information on the effectiveness and use of the pain protocols that the consultant can refer to when evaluating the medical facility's current practices. The consultant establishes a medical director of pain management who then works with the consultant to create a pain protocol plan. The consultant helps the facility implement the plan and monitors the success of the pain management procedures. The database is updated based on the results of this monitoring. The updated database is then shared over the network with other medical facilities.
Patients hospitalized for TM after a proximal ischemic stroke of the middle cerebral artery and whose reperfusion is satisfactory (TICI 2b, 2c and 3). Additional blood sample will be taken during usual treatment the day of the stroke.
In this study, we will recruit 180 adolescents and young adults (ages 14-25) with type 1 diabetes for at least 1 year and suboptimal diabetes control (A1c 7-13%) to participate in a 2-year randomized clinical trial aimed at reducing diabetes distress and improving glycemic outcomes. Adolescents and young adults with type 1 diabetes represent a population that often has uncontrolled diabetes with elevated A1c levels and experiences diabetes distress, making such patients ideal for this study. Participants will be randomly assigned to one of two groups (control or intervention). The intervention group will participate in monthly intervention sessions with a research assistant during the first year of the study. Four sessions will focus on improving glycemic outcomes and 8 sessions will focus on reducing diabetes distress. The sessions will be conducted face-to-face or remotely. To ensure adequate recruitment and retention, the control group will participate in the intervention sessions during the second year of the study. Participants in both groups will use continuous glucose monitoring (CGM), with CGM data downloaded every 3 months. Participants in both groups will complete surveys and have A1c measured every 6 months. We will compare the two groups on percent time in target glucose range (70-180 mg/dL), A1c, and diabetes distress from baseline to 1 year. We hypothesize that the intervention group will have an improvement in percent time in range, A1c, and diabetes distress, compared with the control group.
Asthma is the most common chronic disease of childhood, and it disproportionately affects urban, minority, and disadvantaged children. When implemented correctly, existing evidence-based guidelines from the National Heart, Lung, and Blood Institute (NHLBI) improve pediatric asthma care and outcomes. One key component of these guidelines is the importance of longitudinal care as part of a partnership among patient, parents, and a healthcare provider. Such a partnership depends on effective communication of healthcare status by parents to providers. Improving the communication skills of inner-city parents may improve their ability to obtain more effective longitudinal asthma care within their primary care homes and thereby to improve their child's asthma health outcomes. IMPACT DC ("Improving Pediatric Asthma Care in the District of Columbia") is a locally validated emergency department (ED) based intervention that improves multiple measures of asthma care and outcomes through an intensive short-term program of asthma education, medical care, and care coordination. In spite of these successes, achieving increased subsequent contact and partnership with primary care providers (PCPs) for asthma care after the intervention has not been successful. Therefore, for the current study, we propose to assess the effectiveness of an enhanced version of the existing IMPACT DC intervention consisting of short-term case management by trained asthma educators.
The present invention is directed to isolated nucleic acid molecules encoding  Rickettsia felis  outer membrane proteins ( R. felis  omp). Expression vectors and host cells comprising the nucleic acid molecules are also provided, as well as methods for increasing or decreasing the expression of  R. felis  omp in host cells. The invention further provides a method of screening a substance for the ability of the substance to modify  R. felis  omp function, and a method for isolating other  R. felis  omp molecules. DNA oligomers capable of hybridizing to the nucleic acid molecule encoding the  R. felis  omp are provided, which can be used to detect  R. felis  omp in a sample. An isolated  R. felis  omp is also provided. Antibodies specific for the protein, and fragments thereof, are provided, as are compositions comprising the protein and a compatible carrier. The subject invention further provides a method of preventing  R. felis  infections by  R. felis  present in a carrier host, and a method of reducing  R. felis  infection of a carrier host.
This invention provides modified IGFBP-derived peptides ? collectively termed "immodulator peptides" ? and related compositions and methods. Chemical modifications to peptides using small molecules, and sequence extensions to immodulator core sequences exhibit new and surprising biological activities. The invention builds the combinatorial power of the immodulator peptide class further by demonstrating which core sequences bind metal or glycosaminoglycans such as heparin. The invention discloses some surprising biological properties of compositions derived from these modifications, including a host of new therapeutic and diagnostic utilities ( e.g. immune modulation of TLR signaling, enhanced collagen synthesis by skin fibroblasts, and synergy with a RIG-1 agonist in killing melanoma cells). The invention also teaches methods for enhancing previously disclosed uses of immodulator peptides by showing how the modifications of the invention can boost the efficacy of immodulator peptides in a model of burn trauma.
PURPOSE: Here, we report the sensitivity of a personalized, tumor-informed circulating tumor DNA (ctDNA) assay (Signatera) for detection of molecular relapse during long-term follow-up of patients with breast cancer.
METHODS: A total of 156 patients with primary breast cancer were monitored clinically for up to 12 years after surgery and adjuvant chemotherapy. Semiannual blood samples were prospectively collected, and analyzed retrospectively to detect residual disease by ultradeep sequencing using ctDNA assays, developed from primary tumor whole-exome sequencing data.
RESULTS: Personalized Signatera assays detected ctDNA ahead of clinical or radiologic relapse in 30 of the 34 patients who relapsed (patient-level sensitivity of 88.2%). Relapse was predicted with a lead interval of up to 38 months (median, 10.5 months; range, 0-38 months), and ctDNA positivity was associated with shorter relapse-free survival (P < .0001) and overall survival (P < .0001). All relapsing triple-negative patients (n = 7/23) had a ctDNA-positive test within a median of 8 months (range, 0-19 months), while the 16 nonrelapsed patients with triple-negative breast cancer remained ctDNA-negative during a median follow-up of 58 months (range, 8-99 months). The four patients who had negative tests before relapse all had hormone receptor-positive (HR+) disease and conversely, five of the 122 nonrelapsed patients (all HR+) had an occasional positive test.
CONCLUSION: Serial postoperative ctDNA assessment has strong prognostic value, provides a potential window for earlier therapeutic intervention, and may enable more effective monitoring than current clinical tests such as cancer antigen 15-3. Our study provides evidence that those with serially negative ctDNA tests have superior clinical outcomes, providing reassurance to patients with breast cancer. For select cases with HR+ disease, decisions about treatment management might require serial monitoring despite the ctDNA-positive result.
Vitamin D deficiency is one of the most common nutritional conditions among patients with sickle cell disease (SCD). Since vitamin D deficiency and SCD share common manifestations including chronic pain, poor bone health and chronic systemic inflammation, it is reasonable to postulate that vitamin D deficiency may contribute to these complications. Thus, optimizing vitamin D nutrition represents an inexpensive strategy that may improve vitamin D status and health outcomes in SCD children. The working hypothesis is that administration of a single oral bolus of 300,000 IU of vitamin D3 to SCD children will result in the attainment of vitamin D sufficiency (25OHD levels \>75 nmol/L) in 80% of participants after 3 months. The primary objectives are to assess feasibility, acceptability, and safety of the vitamin D3 bolus while secondary objectives are related to the mean change in serum 25OHD from baseline to 3 months post-bolus and its clinical impact. Seventy-two SCD children (5-17 years, SS and SC genotypes) will be randomized to one bolus of 300,000 IU of vitamin D3 or identical placebo. Blood will be collected at baseline and 3-month post-bolus to measure serum 25OHD and calculate the change from baseline at 3 months (efficacy outcomes). Other outcomes include urinary calcium/creatinine ratio and serum calcium (safety), questionnaires (acceptability and musculoskeletal pain) and parameters related to growth, haematology, inflammation and bone health (exploratory outcomes).
PURPOSE:To provide the subject medicine having increasing activity for the blood flow in the choroid, thus useful for the treatment of ischemic choroidal syndrome etc., containing, as active ingredient, a dihydro-keto-ethyl-prostaglandin F. CONSTITUTION:The objective medicine containing, as active ingredient, 13,14- dihydro-15-keto-20-ethyl-prostaglandin F, a salt or a lower alkyl ester thereof. The dose of the active ingredient, when it is to be topically administered on the eyes, is normally 0.1-100mug/eye; or when to be systemically administered either in two to four portions a day or in a continuous mode, is normally 0.001-500mg/kg. This medicine can be prepared, in the form of powder for injection, by, for example, mixing 1 pt.wt. of the active ingredient, 5 pts.wt. of mannitol and 0.4 pts.wt. of sterilized water followed by agitation, sterilization, filtration, and then lyophilization.
PURPOSE: A transdermal drug delivery formulation including tulobuterol HCL as a main ingredient is provided. It continuously delivers tulobuterol HCL and maintains the effective blood concentration of the drug constantly for 24 hours, when applied to the skin. Also, it minimizes the secular aging of the drug in stability and adhesion. CONSTITUTION: The transdermal drug delivery formulation contains a matrix layer including 1 to 5% by weight of tulobuterol HCL, 78 to 97% by weight of acryl-based adhesives, 1 to 20% by weight of skin penetration enhancers and 1 to 20% by weight of diffusion enhancers, based on the total weight of the matrix layer. In the formulation, the matrix layer has a thickness of 40micrometers or more. The acryl-based adhesives contain a monomer including a hydroxyl group as a functional group, the skin penetration enhancers are selected from the group consisting of higher fatty acids, higher fatty acid alcohol, glycerin fatty acid ester, polyethylene glycol sorbitan fatty acid esters, terpenes, sulfoxides, pyrrolidones, amides, N-hydroxy methyl lactide, sorbitol, urea and its derivatives.
The complete cDNA sequences encoding the amino acid sequences corresponding to two tissue-specific subtypes of mammalian vesicle membrane transport protein are disclosed. The two tissue-specific subtypes are adrenal-specific and brain-specific. Complete cDNA sequences are disclosed for rat adrenal-specific and brain-specific transport protein, as well as for human brain-specific transport protein. Methods for obtaining the genes encoding these proteins and for obtaining recombinantly produced protein are described. Antibodies and methods for isolating additional vesicle membrane transport proteins are also described. Methods for using the vesicle membrane transport proteins to identify compounds that selectively inhibit transport of toxic molecules into vesicles, and that prevent inhibition of transport of toxic molecules are also provided. The invention includes methods to treat and diagnose diseases associated with sequestration of toxic molecules in mammalian cells.